 Thiazoles
"Thiazoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D013844
|
| MeSH Number(s) |
D02.886.675 D03.383.129.708
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Thiazoles".
Below are MeSH descriptors whose meaning is more specific than "Thiazoles".
This graph shows the total number of publications written about "Thiazoles" by people in UAMS Profiles by year, and whether "Thiazoles" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2020 | 0 | 1 | 1 | | 2019 | 1 | 1 | 2 | | 2018 | 2 | 1 | 3 | | 2017 | 0 | 1 | 1 | | 2016 | 1 | 1 | 2 | | 2014 | 1 | 2 | 3 | | 2013 | 2 | 2 | 4 | | 2012 | 1 | 1 | 2 | | 2011 | 2 | 0 | 2 | | 2010 | 0 | 2 | 2 | | 2009 | 0 | 1 | 1 | | 2008 | 1 | 1 | 2 | | 2007 | 1 | 1 | 2 | | 2005 | 2 | 3 | 5 | | 2004 | 1 | 2 | 3 | | 2003 | 1 | 2 | 3 | | 2002 | 0 | 1 | 1 | | 2001 | 0 | 1 | 1 | | 2000 | 1 | 1 | 2 | | 1999 | 1 | 1 | 2 | | 1998 | 1 | 2 | 3 | | 1994 | 0 | 1 | 1 | | 1989 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Thiazoles" by people in Profiles over the past ten years.
-
Barnette DA, Schleiff MA, Osborn LR, Flynn N, Matlock M, Swamidass SJ, Miller GP. Dual mechanisms suppress meloxicam bioactivation relative to sudoxicam. Toxicology. 2020 07; 440:152478.
-
Mapplebeck JCS, Lorenzo LE, Lee KY, Gauthier C, Muley MM, De Koninck Y, Prescott SA, Salter MW. Chloride Dysregulation through Downregulation of KCC2 Mediates Neuropathic Pain in Both Sexes. Cell Rep. 2019 07 16; 28(3):590-596.e4.
-
Konstantinopoulos PA, Barry WT, Birrer M, Westin SN, Cadoo KA, Shapiro GI, Mayer EL, O'Cearbhaill RE, Coleman RL, Kochupurakkal B, Whalen C, Curtis J, Farooq S, Luo W, Eismann J, Buss MK, Aghajanian C, Mills GB, Palakurthi S, Kirschmeier P, Liu J, Cantley LC, Kaufmann SH, Swisher EM, D'Andrea AD, Winer E, Wulf GM, Matulonis UA. Olaparib and a-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. Lancet Oncol. 2019 04; 20(4):570-580.
-
Harada Y, Virmani T, Gokden M, Stefans V. Toxic Myopathy due to Antidopaminergic Medication Without Neuroleptic Malignant Syndrome. J Clin Neuromuscul Dis. 2018 Dec; 20(2):94-98.
-
Jain N, Reilly RF. Clinical Pharmacology of Oral Anticoagulants in Patients with Kidney Disease. Clin J Am Soc Nephrol. 2019 02 07; 14(2):278-287.
-
Dang NL, Hughes TB, Miller GP, Swamidass SJ. Computationally Assessing the Bioactivation of Drugs by N-Dealkylation. Chem Res Toxicol. 2018 02 19; 31(2):68-80.
-
Kaatz S, Mahan CE, Nakhle A, Gunasekaran K, Ali M, Lavender R, Paje DG. Management of Elective Surgery and Emergent Bleeding with Direct Oral Anticoagulants. Curr Cardiol Rep. 2017 10 24; 19(12):124.
-
Bender Ignacio RA, Lee JY, Rudek MA, Dittmer DP, Ambinder RF, Krown SE. Brief Report: A Phase 1b/Pharmacokinetic Trial of PTC299, a Novel PostTranscriptional VEGF Inhibitor, for AIDS-Related Kaposi's Sarcoma: AIDS Malignancy Consortium Trial 059. J Acquir Immune Defic Syndr. 2016 May 01; 72(1):52-7.
-
Shah A, Shewale A, Hayes CJ, Martin BC. Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients. Stroke. 2016 06; 47(6):1555-61.
-
Cao J, Forrest JC, Zhang X. A screen of the NIH Clinical Collection small molecule library identifies potential anti-coronavirus drugs. Antiviral Res. 2015 Feb; 114:1-10.
-
Gali R, Banothu J, Gondru R, Bavantula R, Velivela Y, Crooks PA. One-pot multicomponent synthesis of indole incorporated thiazolylcoumarins and their antibacterial, anticancer and DNA cleavage studies. Bioorg Med Chem Lett. 2015 Jan 01; 25(1):106-12.
-
Wilson MP, Minassian A, Bahramzi M, Campillo A, Vilke GM. Despite expert recommendations, second-generation antipsychotics are not often prescribed in the emergency department. J Emerg Med. 2014 Jun; 46(6):808-13.
-
Wilson MP, MacDonald K, Vilke GM, Ronquillo L, Feifel D. Intramuscular ziprasidone: influence of alcohol and benzodiazepines on vital signs in the emergency setting. J Emerg Med. 2013 Dec; 45(6):901-8.
-
Jain P, Kantarjian H, Nazha A, O'Brien S, Jabbour E, Romo CG, Pierce S, Cardenas-Turanzas M, Verstovsek S, Borthakur G, Ravandi F, Quintás-Cardama A, Cortes J. Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. Blood. 2013 Jun 13; 121(24):4867-74.
-
Ghate SR, Porucznik CA, Said Q, Hashibe M, Joy E, Brixner DI. Association between second-generation antipsychotics and changes in body mass index in adolescents. J Adolesc Health. 2013 Mar; 52(3):336-43.
-
Sayegh J, Cao J, Zou MR, Morales A, Blair LP, Norcia M, Hoyer D, Tackett AJ, Merkel JS, Yan Q. Identification of small molecule inhibitors of Jumonji AT-rich interactive domain 1B (JARID1B) histone demethylase by a sensitive high throughput screen. J Biol Chem. 2013 Mar 29; 288(13):9408-17.
-
Dayyani F, Parikh NU, Varkaris AS, Song JH, Moorthy S, Chatterji T, Maity SN, Wolfe AR, Carboni JM, Gottardis MM, Logothetis CJ, Gallick GE. Combined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways. PLoS One. 2012; 7(12):e51189.
-
Radich JP, Kopecky KJ, Appelbaum FR, Kamel-Reid S, Stock W, Malnassy G, Paietta E, Wadleigh M, Larson RA, Emanuel P, Tallman M, Lipton J, Turner AR, Deininger M, Druker BJ. A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood. 2012 Nov 08; 120(19):3898-905.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|